Product Information
DARIFENACIN ER 15 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.4323 per EA under NDC 69097043202. Its NADAC has been published 515 times since Nov 23, 2016.
FDA first approved this application on Sep 1, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15 mg/1
Manufacturer
Cipla USA Inc.NDC
69097043202
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DARIFENACIN HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207664FDA Approved
9/1/2016
TE Code
AB
On Market Since
9/1/2016
Pharmacological Classes
Price Statistics
The NADAC for DARIFENACIN ER 15 MG TABLET has been published 515 times since Nov 23, 2016, and over the history we have for it it has declined 94.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4323 per EA |
|---|---|
| All-time high | $8.1286 (Feb 15, 2017) |
| All-time low | $0.3150 (Mar 19, 2025) |
| 52-week high | $0.4323 |
| 52-week low | $0.3496 |
| Median price | $1.9945 |
| Average price | $2.6963 |
| Largest weekly change | +137.4% (Jun 23, 2021) |
| Weeks tracked | 515 |
| Tracking since | Nov 23, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Darifenacin Hydrobromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DARIFENACIN ER 15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DARIFENACIN ER 15 MG TABLET, manufactured by Cipla USA Inc., is $0.4323 per EA (NDC 69097043202), effective Sep 30, 2026.
How has the price of DARIFENACIN ER 15 MG TABLET changed over time?
Over the history we have for it, the NADAC for DARIFENACIN ER 15 MG TABLET has declined 94.5%. It has been tracked across 515 weekly CMS publications since Nov 23, 2016.
What are the highest and lowest recorded NADAC prices for DARIFENACIN ER 15 MG TABLET?
Since Nov 23, 2016, the NADAC for DARIFENACIN ER 15 MG TABLET has ranged from a low of $0.3150 (Mar 19, 2025) to a high of $8.1286 (Feb 15, 2017), with a median of $1.9945 per EA.
Are there cheaper alternatives to DARIFENACIN ER 15 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DARIFENACIN ER 15 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DARIFENACIN ER 15 MG TABLET?
DARIFENACIN ER 15 MG TABLET (NDC 69097043202) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.